Hongqi Tian - Search Results

Year	Number of Results
1999	1
2002	1
2005	1
2007	1
2012	1
2013	2
2014	1
2016	1
2017	1
2018	4
2019	5
2020	6
2021	7
2022	3
2023	5
2024	1

1

Metal-Organic Framework (MOF)-Based Drug Delivery.

Cao J, Li X, Tian H. Cao J, et al. Among authors: tian h. Curr Med Chem. 2020;27(35):5949-5969. doi: 10.2174/0929867326666190618152518. Curr Med Chem. 2020. PMID: 31215374 Review.

2

Current Development Status of MEK Inhibitors.

Cheng Y, Tian H. Cheng Y, et al. Among authors: tian h. Molecules. 2017 Sep 26;22(10):1551. doi: 10.3390/molecules22101551. Molecules. 2017. PMID: 28954413 Free PMC article. Review.

3

Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands.

Li X, Liu Y, Tian H. Li X, et al. Among authors: tian h. Bioinorg Chem Appl. 2018 Oct 1;2018:8276139. doi: 10.1155/2018/8276139. eCollection 2018. Bioinorg Chem Appl. 2018. PMID: 30402082 Free PMC article. Review.

4

Development of ERK1/2 inhibitors as a therapeutic strategy for tumour with MAPK upstream target mutations.

Miao L, Tian H. Miao L, et al. Among authors: tian h. J Drug Target. 2020 Feb;28(2):154-165. doi: 10.1080/1061186X.2019.1648477. Epub 2019 Aug 13. J Drug Target. 2020. PMID: 31340679 Review.

5

Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy.

Li K, Tian H. Li K, et al. Among authors: tian h. J Drug Target. 2019 Mar;27(3):244-256. doi: 10.1080/1061186X.2018.1440400. Epub 2018 Feb 20. J Drug Target. 2019. PMID: 29448849 Review.

6

A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma.

Wei X, Zou Z, Zhang W, Fang M, Zhang X, Luo Z, Chen J, Huang G, Zhang P, Cheng Y, Liu J, Liu J, Zhang J, Wu D, Chen Y, Ma X, Pan H, Jiang R, Liu X, Ren X, Tian H, Jia Z, Guo J, Si L. Wei X, et al. Among authors: tian h. Eur J Cancer. 2024 May;202:114008. doi: 10.1016/j.ejca.2024.114008. Epub 2024 Mar 11. Eur J Cancer. 2024. PMID: 38479118 Clinical Trial.

7

Protective mechanism of a novel aminothiol compound on radiation-induced intestinal injury.

Wang X, Yuan R, Miao L, Li X, Guo Y, Tian H. Wang X, et al. Among authors: tian h. Int J Radiat Biol. 2023;99(2):259-269. doi: 10.1080/09553002.2022.2074163. Epub 2022 May 27. Int J Radiat Biol. 2023. PMID: 35583501

8

Radioprotective effects and mechanism of HL-003 on radiation-induced salivary gland damage in mice.

Ren J, Huang R, Li Y, Chen R, Tian H, Liu C. Ren J, et al. Among authors: tian h. Sci Rep. 2022 May 19;12(1):8419. doi: 10.1038/s41598-022-12581-y. Sci Rep. 2022. PMID: 35589816 Free PMC article.

9

KZ02 enhances the radiosensitivity of BRAF-mutated CRC in vitro and in vivo.

Guo Y, Li X, Yuan R, Ren J, Huang Y, Yu Y, Tian H. Guo Y, et al. Among authors: tian h. Eur J Pharmacol. 2023 Nov 15;959:176060. doi: 10.1016/j.ejphar.2023.176060. Epub 2023 Sep 27. Eur J Pharmacol. 2023. PMID: 37775019

10

Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2.

Blake JF, Gaudino JJ, De Meese J, Mohr P, Chicarelli M, Tian H, Garrey R, Thomas A, Siedem CS, Welch MB, Kolakowski G, Kaus R, Burkard M, Martinson M, Chen H, Dean B, Dudley DA, Gould SE, Pacheco P, Shahidi-Latham S, Wang W, West K, Yin J, Moffat J, Schwarz JB. Blake JF, et al. Among authors: tian h. Bioorg Med Chem Lett. 2014 Jun 15;24(12):2635-9. doi: 10.1016/j.bmcl.2014.04.068. Epub 2014 Apr 29. Bioorg Med Chem Lett. 2014. PMID: 24813737

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

37 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year